Colestilan Chloride

Summary

Colestilan Chloride (CHEMBL2103800) is an approved small molecule (ATC V03AE06); indicated across 3 conditions including hyperphosphatemia and chronic kidney disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: V03AE06
• Indications: 3 conditions
• Clinical trials: 9

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2103800
Name	Colestilan Chloride
Type	Small molecule
Max phase	4
ATC	V03AE06

Also known as: Bindren, Cholebine, Cholebine (japan), Colestilan, Colestilan chloride, Colestimide, MCI-196, COLESTILAN CHLORIDE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hyperphosphatemia	4	MONDO:0000328	HP:0002905
chronic kidney disease	3	MONDO:0005300	EFO:0003884
type 2 diabetes mellitus	2	MONDO:0005148	MONDO:0005148

Clinical trials

Total trials: 9.

Phase distribution

Phase	Trials
PHASE3	7
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00506441	PHASE3	COMPLETED	A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia
NCT00542386	PHASE3	COMPLETED	A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia
NCT00542815	PHASE3	COMPLETED	A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia
NCT00772382	PHASE3	COMPLETED	Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia
NCT00858637	PHASE3	COMPLETED	Efficacy and Safety Study of MCI-196 Versus Simvastatin for Dyslipidaemia in Chronic Kidney Disease (CKD) Subjects on Dialysis
NCT01814917	PHASE3	TERMINATED	Long-term Extension Study of MCI-196
NCT01818687	PHASE3	TERMINATED	Safety and Tolerability Study of MCI-196
NCT00497198	PHASE2	COMPLETED	Efficacy and Safety Study of MCI-196 in Patients With Type 2 Diabetes
NCT01976572	PHASE1	COMPLETED	Drug-Drug Interaction Study to Evaluate the Effect of Colestilan on the Pharmacokinetics of Single Doses of Candesartan Cilexetil in Healthy Subjects

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).